A pharmaceutical formulation comprising atorvastatin calcium as active ingredient and a pH adjusting substance, in which atorvastatin calcium is micronized amorphous atorvastatin calcium, and the amount of the pH adjusting substance is adjusted in the pharmaceutical formulation such that a single administration of the formulation increases the pH in 900 ml of an aqueous 0.001 M HCl solution of pH 3 to pH equal to or greater than pKa+1 of atorvastatin calcium, wherein the pH adjusting substance is contained in the pharmaceutical formulation in an amount of 0.2 to 2.0 mmol and being MgO. Described is also a method for the preparation and use of a solid formulation.A pharmaceutical formulation comprising atorvastatin calcium as active ingredient and a pH adjusting substance, in which atorvastatin calcium is micronized amorphous atorvastatin calcium, and the amount of the pH adjusting substance is adjusted in the pharmaceutical formulation such that a single administration of the formulation increases the pH in 900 ml of an aqueous 0.001 M HCl solution of pH 3 to pH equal to or greater than pKa+1 of atorvastatin calcium, wherein the pH adjusting substance is contained in the pharmaceutical formulation in an amount of 0.2 to 2.0 mmol and being MgO. Described is also a method for the preparation and use of a solid formulation.
